Find Posenacaftor manufacturers, exporters & distributors on PharmaCompass

Posenacaftor

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

2DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Posenacaftor [usan], Bn5ut8i0t9, Pti-801, 2095064-05-2, Posenacaftor (usan), Posenacaftor [inn]

Molecular Formula

C₂₇H₂₇NO₅

Molecular Weight

445.5 g/mol

InChI Key

QUDOHCFOJCNKPK-QGZVFWFLSA-N

FDA UNII

BN5UT8I0T9

PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.

1 2D Structure

Posenacaftor

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

8-methyl-2-(3-methyl-1-benzofuran-2-yl)-5-[(1R)-1-(oxan-4-yl)ethoxy]quinoline-4-carboxylic acid

2.1.2 InChI

InChI=1S/C27H27NO5/c1-15-8-9-23(32-17(3)18-10-12-31-13-11-18)24-20(27(29)30)14-21(28-25(15)24)26-16(2)19-6-4-5-7-22(19)33-26/h4-9,14,17-18H,10-13H2,1-3H3,(H,29,30)/t17-/m1/s1

2.1.3 InChI Key

QUDOHCFOJCNKPK-QGZVFWFLSA-N

2.1.4 Canonical SMILES

CC1=C2C(=C(C=C1)OC(C)C3CCOCC3)C(=CC(=N2)C4=C(C5=CC=CC=C5O4)C)C(=O)O

2.1.5 Isomeric SMILES

CC1=C2C(=C(C=C1)O[C@H](C)C3CCOCC3)C(=CC(=N2)C4=C(C5=CC=CC=C5O4)C)C(=O)O

2.2 Other Identifiers

2.2.1 UNII

BN5UT8I0T9

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Posenacaftor [usan]

2. Bn5ut8i0t9

3. Pti-801

4. 2095064-05-2

5. Posenacaftor (usan)

6. Posenacaftor [inn]

7. Unii-bn5ut8i0t9

8. Posenacaftor [who-dd]

9. Chembl4594274

10. Schembl18736773

11. Glxc-25544

12. Who 11276

13. Hy-109187

14. Cs-0116460

15. D11683

16. (r)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2h-pyran-4- Yl)ethoxy)quinoline-4-carboxylate

17. 4-quinolinecarboxylic Acid, 8-methyl-2-(3-methyl-2-benzofuranyl)-5-((1r)-1-(tetrahydro-2h-pyran-4-yl)ethoxy)

18. 4-quinolinecarboxylic Acid, 8-methyl-2-(3-methyl-2-benzofuranyl)-5-((1r)-1-(tetrahydro-2h-pyran-4-yl)ethoxy)-

19. 8-methyl-2-(3-methyl-1-benzofuran-2-yl)-5-[(1r)-1-(oxan-4-yl)ethoxy]quinoline-4-carboxylic Acid

20. 8-methyl-2-(3-methylbenzofuran-2-yl)-5-((1r)-1-(oxan-4-yl)ethoxy)quinoline-4-carboxylic Acid

2.4 Create Date

2017-08-04

3 Chemical and Physical Properties

Molecular Formula	C₂₇H₂₇NO₅
Molecular Weight	445.5 g/mol
XLogP3	5.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	5
Exact Mass	445.18892296 g/mol
Monoisotopic Mass	445.18892296 g/mol
Topological Polar Surface Area	81.8 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	681
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in addictions, osteoarthritis, and pain (acute or chronic).

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

PTI-801 is a novel form of oxycodone that minimizes the abuse and drug dependence that is often associated with oxycodone and other narcotic painkillers. The goal of developing PTI-801 is to ensure the safety of patients who have a legitimate medical need to treat severe chronic pain with a narcotic painkiller, and to protect the public from the consequences of abuse.

Drugs in Development